These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17970893)

  • 1. Off-label uses of rituximab in dermatology.
    Carr DR; Heffernan MP
    Dermatol Ther; 2007; 20(4):277-87. PubMed ID: 17970893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative uses of rituximab in dermatology.
    Carr DR; Heffernan MP
    Dermatol Clin; 2010 Jul; 28(3):547-57. PubMed ID: 20510764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.
    Schadlow MB; Anhalt GJ; Sinha AA
    J Drugs Dermatol; 2003 Oct; 2(5):564-7. PubMed ID: 14558407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in non-haematological disorders of adults and its mode of action.
    McDonald V; Leandro M
    Br J Haematol; 2009 Aug; 146(3):233-46. PubMed ID: 19466979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: applications in dermatology.
    Fatourechi MM; el-Azhary RA; Gibson LE
    Int J Dermatol; 2006 Oct; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: Uses in Dermatology.
    Gleghorn K; Wilson J; Wilkerson M
    Skin Therapy Lett; 2016 Sep; 21(5):5-7. PubMed ID: 27603326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK; Posner MR; Spigelman Z; Ahmed AR
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R; Looney RJ
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
    Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
    Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of rituximab in cutaneous medicine.
    Scheinfeld N
    Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.
    Barnadas M; Roe E; Brunet S; Garcia P; Bergua P; Pimentel L; Puig L; Francia A; García R; Gelpí C; Sierra J; Coll P; Alomar A
    J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):69-74. PubMed ID: 16405612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.
    Heizmann M; Itin P; Wernli M; Borradori L; Bargetzi MJ
    Am J Hematol; 2001 Feb; 66(2):142-4. PubMed ID: 11421295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X; Hu W; Qin X
    Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P; Dörner T; Tony HP
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.